CA2029353C - Stabilisation d'echantillons pour l'analyse microbienne - Google Patents

Stabilisation d'echantillons pour l'analyse microbienne

Info

Publication number: CA2029353C
Authority: CA; Canada
Prior art keywords: specimen; microorganisms; transport system; container; piston
Prior art date: 1990-11-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2029353

Other languages

English (en)

Other versions

CA2029353A1 (fr

Inventor

Gordon L. Dorn

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-06

Filing date

1990-11-06

Publication date

1997-07-29

1990-11-06 Application filed by Individual filed Critical Individual

1990-11-06 Priority to CA 2029353 priority Critical patent/CA2029353C/fr

1992-05-07 Publication of CA2029353A1 publication Critical patent/CA2029353A1/fr

1997-07-29 Application granted granted Critical

1997-07-29 Publication of CA2029353C publication Critical patent/CA2029353C/fr

2010-11-06 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000000813 microbial effect Effects 0.000 title claims abstract description 43
238000004458 analytical method Methods 0.000 title abstract description 26
230000006641 stabilisation Effects 0.000 title description 2
238000011105 stabilization Methods 0.000 title description 2
244000005700 microbiome Species 0.000 claims abstract description 138
238000000034 method Methods 0.000 claims abstract description 81
239000000126 substance Substances 0.000 claims abstract description 39
239000012530 fluid Substances 0.000 claims abstract description 31
239000003795 chemical substances by application Substances 0.000 claims description 69
239000003814 drug Substances 0.000 claims description 48
229940079593 drug Drugs 0.000 claims description 45
230000012010 growth Effects 0.000 claims description 38
229920001817 Agar Polymers 0.000 claims description 32
239000008272 agar Substances 0.000 claims description 32
102000004190 Enzymes Human genes 0.000 claims description 30
108090000790 Enzymes Proteins 0.000 claims description 30
230000010076 replication Effects 0.000 claims description 29
230000003115 biocidal effect Effects 0.000 claims description 27
239000000243 solution Substances 0.000 claims description 26
229910001868 water Inorganic materials 0.000 claims description 25
239000003242 anti bacterial agent Substances 0.000 claims description 23
230000035899 viability Effects 0.000 claims description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
229920002472 Starch Polymers 0.000 claims description 21
235000019698 starch Nutrition 0.000 claims description 21
239000008107 starch Substances 0.000 claims description 21
230000002147 killing effect Effects 0.000 claims description 19
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 18
239000011734 sodium Substances 0.000 claims description 18
229910052708 sodium Inorganic materials 0.000 claims description 17
239000000654 additive Substances 0.000 claims description 16
230000000996 additive effect Effects 0.000 claims description 16
239000004599 antimicrobial Substances 0.000 claims description 13
238000010790 dilution Methods 0.000 claims description 12
239000012895 dilution Substances 0.000 claims description 12
102000001554 Hemoglobins Human genes 0.000 claims description 10
108010054147 Hemoglobins Proteins 0.000 claims description 10
230000003247 decreasing effect Effects 0.000 claims description 8
238000003780 insertion Methods 0.000 claims description 8
230000037431 insertion Effects 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
230000000295 complement effect Effects 0.000 claims description 7
235000006180 nutrition needs Nutrition 0.000 claims description 6
125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
238000000151 deposition Methods 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
206010020852 Hypertonia Diseases 0.000 claims description 3
230000003385 bacteriostatic effect Effects 0.000 claims description 3
230000003139 buffering effect Effects 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims 2
LFORPQYIKMHOCK-UHFFFAOYSA-M sodium;3-methylbutyl sulfate Chemical compound [Na+].CC(C)CCOS([O-])(=O)=O LFORPQYIKMHOCK-UHFFFAOYSA-M 0.000 claims 2
239000000203 mixture Substances 0.000 abstract description 43
238000012360 testing method Methods 0.000 abstract description 24
230000006872 improvement Effects 0.000 abstract description 5
239000007864 aqueous solution Substances 0.000 abstract description 4
230000032258 transport Effects 0.000 description 238
210000004369 blood Anatomy 0.000 description 139
239000008280 blood Substances 0.000 description 139
244000052769 pathogen Species 0.000 description 50
210000002700 urine Anatomy 0.000 description 50
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
238000011084 recovery Methods 0.000 description 37
235000002639 sodium chloride Nutrition 0.000 description 32
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 31
150000003522 tetracyclines Chemical class 0.000 description 30
229960002433 cysteine Drugs 0.000 description 28
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 27
238000005119 centrifugation Methods 0.000 description 27
JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 26
OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 24
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 24
235000018417 cysteine Nutrition 0.000 description 24
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 23
244000000010 microbial pathogen Species 0.000 description 22
229940071127 thioglycolate Drugs 0.000 description 22
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 21
230000000694 effects Effects 0.000 description 21
239000011780 sodium chloride Substances 0.000 description 21
229960002180 tetracycline Drugs 0.000 description 21
239000004098 Tetracycline Substances 0.000 description 20
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 20
229930101283 tetracycline Natural products 0.000 description 20
235000019364 tetracycline Nutrition 0.000 description 20
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 20
229960000707 tobramycin Drugs 0.000 description 20
229940088710 antibiotic agent Drugs 0.000 description 19
150000001875 compounds Chemical class 0.000 description 19
230000004083 survival effect Effects 0.000 description 19
229930182566 Gentamicin Natural products 0.000 description 17
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 17
229960002518 gentamicin Drugs 0.000 description 17
235000013305 food Nutrition 0.000 description 16
229960000433 latamoxef Drugs 0.000 description 16
WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 16
GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 15
229960005091 chloramphenicol Drugs 0.000 description 15
241000194017 Streptococcus Species 0.000 description 14
229960003012 cefamandole Drugs 0.000 description 14
230000001717 pathogenic effect Effects 0.000 description 14
241000588697 Enterobacter cloacae Species 0.000 description 13
GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 13
229960002682 cefoxitin Drugs 0.000 description 13
229930182555 Penicillin Natural products 0.000 description 12
229960000723 ampicillin Drugs 0.000 description 12
239000000843 powder Substances 0.000 description 12
150000003839 salts Chemical class 0.000 description 12
208000012868 Overgrowth Diseases 0.000 description 11
241000191967 Staphylococcus aureus Species 0.000 description 11
229960000603 cefalotin Drugs 0.000 description 11
VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 11
239000001963 growth medium Substances 0.000 description 11
235000015097 nutrients Nutrition 0.000 description 11
JFNWFXVFBDDWCX-UHFFFAOYSA-N sulfisoxazole acetyl Chemical compound C=1C=C(N)C=CC=1S(=O)(=O)N(C(=O)C)C=1ON=C(C)C=1C JFNWFXVFBDDWCX-UHFFFAOYSA-N 0.000 description 11
229950006904 sulfisoxazole acetyl Drugs 0.000 description 11
229960004261 cefotaxime Drugs 0.000 description 10
AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 10
229960003276 erythromycin Drugs 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
108090000204 Dipeptidase 1 Proteins 0.000 description 9
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 9
230000009471 action Effects 0.000 description 9
102000006635 beta-lactamase Human genes 0.000 description 9
238000011109 contamination Methods 0.000 description 9
239000011521 glass Substances 0.000 description 9
239000007788 liquid Substances 0.000 description 9
239000002585 base Substances 0.000 description 8
229960002292 piperacillin Drugs 0.000 description 8
238000004321 preservation Methods 0.000 description 8
230000005180 public health Effects 0.000 description 8
239000007787 solid Substances 0.000 description 8
229930186147 Cephalosporin Natural products 0.000 description 7
238000013459 approach Methods 0.000 description 7
230000000903 blocking effect Effects 0.000 description 7
FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 7
229940124587 cephalosporin Drugs 0.000 description 7
239000012458 free base Substances 0.000 description 7
229940049954 penicillin Drugs 0.000 description 7
RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000012545 processing Methods 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
230000008901 benefit Effects 0.000 description 6
229960003669 carbenicillin Drugs 0.000 description 6
229960004682 cefoperazone Drugs 0.000 description 6
230000034994 death Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
238000002156 mixing Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
229920000742 Cotton Polymers 0.000 description 5
-1 L-cystelne Chemical class 0.000 description 5
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 5
241001163743 Perlodes Species 0.000 description 5
241000193998 Streptococcus pneumoniae Species 0.000 description 5
241000193996 Streptococcus pyogenes Species 0.000 description 5
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 5
229940126575 aminoglycoside Drugs 0.000 description 5
239000007330 chocolate agar Substances 0.000 description 5
229960003085 meticillin Drugs 0.000 description 5
150000002960 penicillins Chemical class 0.000 description 5
229940031000 streptococcus pneumoniae Drugs 0.000 description 5
OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 4
241000588769 Proteus <enterobacteria> Species 0.000 description 4
206010040047 Sepsis Diseases 0.000 description 4
229960004821 amikacin Drugs 0.000 description 4
239000006161 blood agar Substances 0.000 description 4
150000001780 cephalosporins Chemical class 0.000 description 4
229910017052 cobalt Inorganic materials 0.000 description 4
239000010941 cobalt Substances 0.000 description 4
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
230000009849 deactivation Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000002651 drug therapy Methods 0.000 description 4
229920001971 elastomer Polymers 0.000 description 4
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
230000036541 health Effects 0.000 description 4
230000002934 lysing effect Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002674 ointment Substances 0.000 description 4
208000013223 septicemia Diseases 0.000 description 4
239000002594 sorbent Substances 0.000 description 4
241000894007 species Species 0.000 description 4
230000001954 sterilising effect Effects 0.000 description 4
238000004659 sterilization and disinfection Methods 0.000 description 4
229960004659 ticarcillin Drugs 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
241001153886 Ami Species 0.000 description 3
BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 3
241000194032 Enterococcus faecalis Species 0.000 description 3
241000606768 Haemophilus influenzae Species 0.000 description 3
241000588747 Klebsiella pneumoniae Species 0.000 description 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
206010036790 Productive cough Diseases 0.000 description 3
241000589516 Pseudomonas Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108010059993 Vancomycin Proteins 0.000 description 3
239000003708 ampul Substances 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
235000010331 calcium propionate Nutrition 0.000 description 3
239000004330 calcium propionate Substances 0.000 description 3
HOKIDJSKDBPKTQ-GLXFQSAKSA-N cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000006174 pH buffer Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
238000007747 plating Methods 0.000 description 3
239000001397 quillaja saponaria molina bark Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
229930182490 saponin Natural products 0.000 description 3
150000007949 saponins Chemical class 0.000 description 3
210000003802 sputum Anatomy 0.000 description 3
208000024794 sputum Diseases 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
241000606790 Haemophilus Species 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108010093965 Polymyxin B Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
241001221452 Staphylococcus faecalis Species 0.000 description 2
239000002250 absorbent Substances 0.000 description 2
230000002745 absorbent Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000003899 bactericide agent Substances 0.000 description 2
239000000022 bacteriostatic agent Substances 0.000 description 2
235000015278 beef Nutrition 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000009640 blood culture Methods 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
235000019365 chlortetracycline Nutrition 0.000 description 2
229960002227 clindamycin Drugs 0.000 description 2
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003172 expectorant agent Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
229940047650 haemophilus influenzae Drugs 0.000 description 2
239000000413 hydrolysate Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000002906 microbiologic effect Effects 0.000 description 2
229940066491 mucolytics Drugs 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
230000035939 shock Effects 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000004222 uncontrolled growth Effects 0.000 description 2
229960003165 vancomycin Drugs 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
KCVTVKMPZQSSNU-UHFFFAOYSA-N 2-pyridin-4-ylethanethioyl chloride Chemical compound ClC(=S)CC1=CC=NC=C1 KCVTVKMPZQSSNU-UHFFFAOYSA-N 0.000 description 1
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
241000606124 Bacteroides fragilis Species 0.000 description 1
108020004256 Beta-lactamase Proteins 0.000 description 1
241000283725 Bos Species 0.000 description 1
238000009631 Broth culture Methods 0.000 description 1
241001660259 Cereus <cactus> Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
241000193470 Clostridium sporogenes Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
206010024774 Localised infection Diseases 0.000 description 1
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
229940123973 Oxygen scavenger Drugs 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000004105 Penicillin G potassium Substances 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
241000009298 Trigla lyra Species 0.000 description 1
208000012931 Urologic disease Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
229960003311 ampicillin trihydrate Drugs 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
238000011203 antimicrobial therapy Methods 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
MJOUVQKVCMZNBV-GDUWRUPCSA-N azane;(6r,7r)-7-[[(2r)-2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N.N.C1([C@@H](C(O)=O)C(=O)N[C@]2(OC)C(N3C(=C(CSC=4N(N=NN=4)C)CO[C@@H]32)C(O)=O)=O)=CC=C(O)C=C1 MJOUVQKVCMZNBV-GDUWRUPCSA-N 0.000 description 1
229940098166 bactrim Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 description 1
229960005255 carbenicillin disodium Drugs 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
229960002727 cefotaxime sodium Drugs 0.000 description 1
229960003016 cefoxitin sodium Drugs 0.000 description 1
XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000002289 effect on microbe Effects 0.000 description 1
239000000806 elastomer Substances 0.000 description 1
229960005194 erythromycin gluceptate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
239000004571 lime Substances 0.000 description 1
VLJXYASGGIMGRO-CFOLLTDRSA-M lithium;(6r,7r)-7-[[(2r)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Li+].CN1N=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 VLJXYASGGIMGRO-CFOLLTDRSA-M 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
229940019826 methicillin sodium Drugs 0.000 description 1
MGFZNWDWOKASQZ-UMLIZJHQSA-M methicillin sodium Chemical compound [Na+].COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 MGFZNWDWOKASQZ-UMLIZJHQSA-M 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
229960001994 mezlocillin sodium Drugs 0.000 description 1
230000027939 micturition Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000019368 penicillin G potassium Nutrition 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
229960005264 piperacillin sodium Drugs 0.000 description 1
210000004910 pleural fluid Anatomy 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000024 polymyxin B Polymers 0.000 description 1
229960005266 polymyxin b Drugs 0.000 description 1
229960003548 polymyxin b sulfate Drugs 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000010865 sewage Substances 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
239000004945 silicone rubber Substances 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229940075554 sorbate Drugs 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000004326 stimulated echo acquisition mode for imaging Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005404 sulfamethoxazole Drugs 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960004075 ticarcillin disodium Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000006163 transport media Substances 0.000 description 1
239000006150 trypticase soy agar Substances 0.000 description 1
208000014001 urinary system disease Diseases 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
229960001572 vancomycin hydrochloride Drugs 0.000 description 1
LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000013022 venting Methods 0.000 description 1

Landscapes

Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA 2029353 1990-11-06 1990-11-06 Stabilisation d'echantillons pour l'analyse microbienne Expired - Fee Related CA2029353C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2029353 CA2029353C (fr)	1990-11-06	1990-11-06	Stabilisation d'echantillons pour l'analyse microbienne

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2029353 CA2029353C (fr)	1990-11-06	1990-11-06	Stabilisation d'echantillons pour l'analyse microbienne

Publications (2)

Publication Number	Publication Date
CA2029353A1 CA2029353A1 (fr)	1992-05-07
CA2029353C true CA2029353C (fr)	1997-07-29

Family

ID=4146348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2029353 Expired - Fee Related CA2029353C (fr)	1990-11-06	1990-11-06	Stabilisation d'echantillons pour l'analyse microbienne

Country Status (1)

Country	Link
CA (1)	CA2029353C (fr)

1990
- 1990-11-06 CA CA 2029353 patent/CA2029353C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2029353A1 (fr)	1992-05-07

Legal Events

Date	Code	Title	Description
1990-11-06	EEER	Examination request
2004-11-08	MKLA	Lapsed

Publication	Publication Date	Title
US5108927A (en)	1992-04-28	Specimen transport device containing a specimen stabilizing composition
US5070014A (en)	1991-12-03	Stabilization of specimens for microbial analysis
Stuart et al.	1954	The problem of transport of specimens for culture of gonococci
STEVENS JR et al.	1953	Fatal transfusion reactions from contamination of stored blood by cold growing bacteria
Castellote et al.	1990	Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis.
US5155039A (en)	1992-10-13	Apparatus for methods for preserving, transporting storing, re-hydrating and delivering viable micro-organisms
Coonrod et al.	1971	Bacillus cereus pneumonia and bacteremia: A case report
Mårdh et al.	1981	Toxic effect of sampling swabs and transportation test tubes on the formation of intracytoplasmic inclusions of Chlamydia trachomatis in McCoy cell cultures.
Schwella et al.	1994	Microbiologic contamination of peripheral blood stem cell autografts
KR101496477B1 (ko)	2015-02-26	크로마토그래피 매질 및 크로마토그래피 장치 보관 용액 및 이들의 용도
EP0107070B1 (fr)	1988-11-17	Détection de pathogènes microbiennes
CA2176810A1 (fr)	1995-06-08	Procede destine a ameliorer l'extraction quantitative de micro-organismes a partir d'eprouvettes contenant des constituants sanguins
Barry et al.	1972	Efficiency of a transport medium for the recovery of aerobic and anaerobic bacteria from applicator swabs
Khuu et al.	2004	Comparison of automated culture systems with a CFR/USP-compliant method for sterility testing of cell-therapy products
Illert et al.	1995	Bacterial contamination of single‐donor blood components
EP1503770B1 (fr)	2010-03-24	Procede de conservation prolongee de sang et de composants sanguins
US4768653A (en)	1988-09-06	Urine specimen maintenance formula
EP0484579A1 (fr)	1992-05-13	Stabilisation de spécimens pour analyse microbiologique
WO1993002210A1 (fr)	1993-02-04	Dispositif et procedes de conservation, transport, stockage, rehydratation et administration de micro-organismes viables
JP2014510731A (ja)	2014-05-01	赤血球製剤および血小板製剤の有効貯蔵を延ばすための方法および材料
US4726950A (en)	1988-02-23	Urine specimen maintenance formula
US20130143196A1 (en)	2013-06-06	Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
Holmes et al.	1979	The growth of micro-organisms in parenteral nutrition solutions containing amino acids and sugars
Gnarpe et al.	1970	Conditions affecting the viability of spheroplasts in urine
Traub et al.	1978	Neutralization of human serum lysozyme by sodium polyanethol sulfonate but not by sodium amylosulfate